Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflamm… Read more
Market Cap & Net Worth: Cytosorbents Crp (CTSO)
Cytosorbents Crp (NASDAQ:CTSO) has a market capitalization of $42.71 Million ($42.71 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22611 globally and #7984 in its home market, demonstrating a -16.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cytosorbents Crp's stock price $0.68 by its total outstanding shares 62804305 (62.80 Million).
Cytosorbents Crp Market Cap History: 2015 to 2026
Cytosorbents Crp's market capitalization history from 2015 to 2026. Data shows change from $349.82 Million to $42.71 Million (-19.20% CAGR).
Index Memberships
Cytosorbents Crp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #604 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2002 of 3165 |
Weight: Cytosorbents Crp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cytosorbents Crp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cytosorbents Crp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.61x
Cytosorbents Crp's market cap is 1.61 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $349.82 Million | $4.06 Million | -$8.13 Million | 86.25x | N/A |
| 2016 | $342.28 Million | $8.21 Million | -$11.94 Million | 41.71x | N/A |
| 2017 | $408.23 Million | $13.38 Million | -$8.46 Million | 30.51x | N/A |
| 2018 | $507.46 Million | $20.25 Million | -$17.21 Million | 25.06x | N/A |
| 2019 | $241.80 Million | $22.77 Million | -$19.27 Million | 10.62x | N/A |
| 2020 | $500.55 Million | $39.45 Million | -$7.84 Million | 12.69x | N/A |
| 2021 | $263.15 Million | $40.11 Million | -$24.56 Million | 6.56x | N/A |
| 2022 | $97.35 Million | $34.69 Million | -$32.81 Million | 2.81x | N/A |
| 2023 | $69.71 Million | $31.08 Million | -$29.25 Million | 2.24x | N/A |
| 2024 | $57.15 Million | $35.59 Million | -$20.72 Million | 1.61x | N/A |
Competitor Companies of CTSO by Market Capitalization
Companies near Cytosorbents Crp in the global market cap rankings as of March 18, 2026.
Key companies related to Cytosorbents Crp by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Cytosorbents Crp Historical Marketcap From 2015 to 2026
Between 2015 and today, Cytosorbents Crp's market cap moved from $349.82 Million to $ 42.71 Million, with a yearly change of -19.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $42.71 Million | +6.40% |
| 2025 | $40.14 Million | -29.76% |
| 2024 | $57.15 Million | -18.02% |
| 2023 | $69.71 Million | -28.39% |
| 2022 | $97.35 Million | -63.01% |
| 2021 | $263.15 Million | -47.43% |
| 2020 | $500.55 Million | +107.01% |
| 2019 | $241.80 Million | -52.35% |
| 2018 | $507.46 Million | +24.31% |
| 2017 | $408.23 Million | +19.27% |
| 2016 | $342.28 Million | -2.15% |
| 2015 | $349.82 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Cytosorbents Crp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $42.71 Million USD |
| MoneyControl | $42.71 Million USD |
| MarketWatch | $42.71 Million USD |
| marketcap.company | $42.71 Million USD |
| Reuters | $42.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.